MedTrace Logo

Phase 2 Study of TD-9855 to Treat Fibromyalgia

NCT01693692 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 392

Last updated 2022-03-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study study is to determine whether TD-9855 is effective in treating patients with fibromyalgia.

Conditions

  • Fibromyalgia

Interventions

DRUG

TD-9855 Group 1

DRUG

TD-9855 Group 2

DRUG

Placebo

Sponsors & Collaborators

  • Theravance Biopharma

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Theravance Biopharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-01-31
Completion
2014-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01693692 on ClinicalTrials.gov